744 related articles for article (PubMed ID: 1476875)
21. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.
Choudhary A; Davodeau F; Moreau A; Peyrat MA; Bonneville M; Jotereau F
J Immunol; 1995 Apr; 154(8):3932-40. PubMed ID: 7706731
[TBL] [Abstract][Full Text] [Related]
22. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
23. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
24. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
[TBL] [Abstract][Full Text] [Related]
25. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
26. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody.
Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M
J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231
[TBL] [Abstract][Full Text] [Related]
27. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
28. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD
Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
31. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
32. Establishment of an immortalized T-cell line from lung cancer tissue: phenotypic and functional analyses.
Imahayashi S; So T; Sugaya M; Yasuda M; Eifuku R; Takenoyama M; Hanagiri T; Yoshimatsu T; Oyama T; Yasumoto K
Int J Clin Oncol; 2002 Feb; 7(1):38-44. PubMed ID: 11942048
[TBL] [Abstract][Full Text] [Related]
33. Oligoclonal expansion of V beta 8+ cells in interleukin-2-activated T cells residing in subcutaneous metastatic melanoma.
Morita T; Salmeron MA; Moser RP; Ross MI; Itoh K
Clin Exp Metastasis; 1992 Jan; 10(1):69-76. PubMed ID: 1531124
[TBL] [Abstract][Full Text] [Related]
34. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
35. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
36. Role of low nuclear grading of renal carcinoma cells in the functional profile of tumor-infiltrating T cells.
Puccetti L; Manetti R; Parronchi P; Piccinni MP; Mavilia C; Carini M; Romagnani S; Maggi E
Int J Cancer; 2002 Apr; 98(5):674-81. PubMed ID: 11920635
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
[TBL] [Abstract][Full Text] [Related]
38. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
[TBL] [Abstract][Full Text] [Related]
39. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
40. Differences in the requirement of antigen-presenting cells for long-term growth among cytomegalovirus-specific Th clonotypes.
Santamaria P; Lewis C; Barbosa JJ
Eur J Immunol; 1993 Nov; 23(11):2972-9. PubMed ID: 8223874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
